Kodu・Aktsiate loetelu・PTC Therapeutics Inc

PTC Therapeutics Inc

Suletud

SektorTervishoid

69.05 1.69

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

69.73

Põhinäitajad
By Trading Economics
Sissetulek	132M -2.8M
Müük	108M 273M
P/E Sektori keskmine	7.597 64.641
Aktsiakasum	-0.03
Kasumimarginaal	-1.031
Töötajad	991
EBITDA	35M -36M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+44.35% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	3. nov 2026

Turustatistika
By TradingEconomics
Turukapital	858M 6.3B
Eelmine avamishind	67.36
Eelmine sulgemishind	69.05

Uudiste sentiment

By Acuity

24%

76%

67 / 340 Pingereas Healthcare

PTC Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 19:46 UTC

News

PTC Therapeutics reported second-quarter revenue of $360.52 million and raised its full-year outlook to $1.18 billion to $1.28 billion, with shares advancing today.

31. juuli 2026, 21:01 UTC

PTC Therapeutics Inc shares rose in after-market trading, despite broader market concerns over inflation and interest rates amid rising crude oil prices.

30. juuli 2026, 22:31 UTC

News

PTC Therapeutics raised its 2026 revenue guidance after reporting strong Q2 results, with EPS of $0.92 exceeding estimates. Shares are higher in after-market trading.

29. juuli 2026, 18:26 UTC

PTC Therapeutics Inc shares are lower today, reflecting a broader decline. Market participants await the Federal Reserve's interest rate decision this afternoon.

28. juuli 2026, 18:31 UTC

News

PTC Therapeutics shares are lower as analysts anticipate a 5.6% revenue decline in Q2, contrasting with last year's growth of 24.2%.

27. juuli 2026, 20:06 UTC

PTC Therapeutics Inc shares are lower today amid broader market declines, influenced by falling oil prices and Treasury yields ahead of the Federal Reserve meeting.

22. juuli 2026, 17:16 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid rising crude oil prices affecting the broader market.

21. juuli 2026, 18:01 UTC

PTC Therapeutics shares are higher today, reflecting positive market sentiment. The stock remains near the lower end of its one-month range.

20. juuli 2026, 19:56 UTC

News

PTC Therapeutics shares are lower as Wells Fargo cuts price target to $93.00 from $95.00 while keeping an Overweight rating.

Võrdlus sarnastega

Hinnamuutus

PTC Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

44.35% tõus

12 kuu keskmine prognoos

Keskmine 98.33 USD 44.35%

Kõrge 130 USD

Madal 70 USD

Põhineb 12 Wall Streeti analüütiku instrumendi PTC Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi PTC Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

67 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.